Robert M. Green

TL;DR: It was found that low grade gliomas and viable tumors tended to have lower mitoxantrone concentrations than did other tumor types and necrotic tumors, and in the patient undergoing autopsy, highest mitoxanrone concentrations were found in liver, thyroid and heart.

TL;DR: Pharmacokinetic and bioavailability data suggest that drug contained in erythrocytes plays a major role in toxicity and that idarubicinol may play a larger role inoxicity than does the parent compound.

TL;DR: The very short tissue half-life contrasts with previous observations for human autopsy tissue concentrations of mitoxantrone, doxorubicin, menogaril metabolites, diaziquone, and amsacrine and may help explain the lack of visceral toxicity of these compounds.

TL;DR: In summary, intravesical mitoxantrone is reasonably well tolerated and should be studied further at a dose of 10 mg, which is the dose recommended for phase 2 studies.